Importance of Territory Determination Sample Clauses

Importance of Territory Determination. The territory of the License should primarily be limited to the countries in which the patent registration was granted and/or applications were filed. For example, a European patent application may be licensed in whole or in part for all or part of the territories of the designated contracting states of the European Patent Convention. Combinations of extensions of license to other territories are possible, e.g., where the production under the patented technology is carried out in the country of patent protection and the corresponding product is sold in other countries. Please keep in mind that an obligation imposed on a licensee to pay remuneration (royalties) even if the (otherwise patented) procedure is only used outside the territory of the patent, may be seen as restriction going beyond the scope of the patent. You should seek specific advice for such territorial delimitation always where there is a concern or risk of the License being too broad or too limited.
Sample 1
AutoNDA by SimpleDocs
Importance of Territory Determination. The territory of the License should primarily be limited to the countries in which the software patent registration (if applicable) was granted and/or applications were filed. For example, a European patent application may be licensed in whole or in part for all or part of the territories of the designated contracting states of the European Patent Convention. Combinations of extensions of license to other territories are possible, e.g., where the production under the patented technology is carried out in the country of patent protection and the corresponding product is sold in other countries. Please keep in mind that an obligation imposed on a Licensee to pay remuneration (royalties) even if the (otherwise patented) procedure is only used outside the territory of the patent, may be seen as restriction going beyond the scope of the patent. You should seek specific advice for such territorial delimitation always where there is a concern or risk of the License being too broad or too limited. For software licensing, considering the territorial scope of trademarks and copyright may be more applicable. Disputes between trademark owners and the providers of software often occur because online applications are accessible worldwide and trademarks are territorial in nature. The territorial nature of a trademark or copyright means that trademark rights are limited to the country where they have been granted, used or are well known. A trademark registration does not give the owner worldwide protection, but rather protection in individual/specific territories where the trademark is used in the course of trade. As such, it is possible for a trademark to have different owners in different countries. If applicable, parties should approach the determination of existing territorial protections with diligence and should consult market experts and/or legal professionals in the conduct of due diligence.
Sample 1

Related to Importance of Territory Determination

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Additional Information for Product Development Projects Outcome of product development efforts, such copyrights and license agreements. • Units sold or projected to be sold in California and outside of California. • Total annual sales or projected annual sales (in dollars) of products developed under the Agreement. • Investment dollars/follow-on private funding as a result of Energy Commission funding. • Patent numbers and applications, along with dates and brief descriptions.  Additional Information for Product Demonstrations: • Outcome of demonstrations and status of technology. • Number of similar installations. • Jobs created/retained as a result of the Agreement.

  • Development cooperation 1. The Parties recognise that development cooperation is a crucial element of their Partnership and an essential factor in the realisation of the objectives of this Agreement as laid down in Article 1. This cooperation can take financial and non-financial forms.

  • Co-Curricular Activities G. The enrollment of the student of employees who reside outside the District shall be subject to School Board Policy 3.02(3)f, Out-of-County Students.

  • EXTRA-CURRICULAR ACTIVITIES 1. In this agreement, extra-curricular programs and activities include all those that are beyond the provincially prescribed and locally determined curricula of the school.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Notice of Technological Change (a) For the purpose of technological change, the Employer agrees to provide the Union with as much notice as possible, but in any event not less than sixty (60) days notice of a technological change.

Time is Money Join Law Insider Premium to draft better contracts faster.